These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25871632)

  • 1. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
    Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
    Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
    Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1α.
    Li H; Quan J; Zhang M; Yung BC; Cheng X; Liu Y; Lee YB; Ahn CH; Kim DJ; Lee RJ
    Mol Pharm; 2016 Jul; 13(7):2555-62. PubMed ID: 27253378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
    Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
    Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
    Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles.
    Yan C; Gu J; Zhang Y; Ma K; Lee RJ
    Int J Pharm; 2022 Sep; 625():122074. PubMed ID: 35932928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
    Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
    Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
    Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR; Chan KK; Marcucci G
    Leuk Lymphoma; 2014 Jun; 55(6):1332-6. PubMed ID: 24015841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Jin H; Wang M; Xiong K; Wright J; Young A
    Int J Oncol; 2006 Feb; 28(2):469-78. PubMed ID: 16391803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
    Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
    Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide.
    Yang S; Wang D; Sun Y; Zheng B
    Drug Deliv; 2019 Dec; 26(1):965-974. PubMed ID: 31544540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate receptor-targeted lipid-albumin nanoparticles (F-LAN) for therapeutic delivery of an Akt1 antisense oligonucleotide.
    Li H; Liu Y; Chen L; Liu Q; Qi S; Cheng X; Lee YB; Ahn CH; Kim DJ; Lee RJ
    J Drug Target; 2018; 26(5-6):466-473. PubMed ID: 29376449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
    Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2009; 6(1):221-30. PubMed ID: 19183107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
    Wei X; Dai G; Liu Z; Cheng H; Xie Z; Klisovic R; Marcucci G; Chan KK
    Drug Metab Dispos; 2008 Nov; 36(11):2227-33. PubMed ID: 18653746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle.
    Zheng B; Yang S; Tian Q; Xie Y; Zhang S; Lee RJ
    Anticancer Res; 2019 Apr; 39(4):1785-1793. PubMed ID: 30952718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
    Kirschbaum MH; Frankel P; Synold TW; Xie Z; Yen Y; Popplewell L; Chen R; Aljitawi O; Tuscano JM; Chan KK; Newman EM
    Leuk Lymphoma; 2016 Oct; 57(10):2307-14. PubMed ID: 26895565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
    Ferdinandi ES; Vassilakos A; Lee Y; Lightfoot J; Fitsialos D; Wright JA; Young AH
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):193-205. PubMed ID: 20886212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
    Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
    Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.
    Vassilakos A; Lee Y; Viau S; Feng N; Jin H; Chai V; Wang M; Avolio T; Wright J; Young A
    Int J Oncol; 2009 Jan; 34(1):33-42. PubMed ID: 19082475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antisense oligonucleotide delivery using cationic liposomes incorporating fatty acid-modified polyethylenimine.
    Guo Z; Li Y; Fu Y; Guo T; Li X; Yang S; Xie J
    Curr Pharm Biotechnol; 2014; 15(9):800-5. PubMed ID: 25403516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.